Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.20.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Revenues $ 0 $ 0 $ 0 $ 0
Operating expenses:        
Research and development 4,435,000 2,785,000 10,971,000 7,816,000
General and administrative 1,659,000 1,672,000 5,122,000 4,748,000
Depreciation and amortization 57,000 51,000 154,000 147,000
Total operating expenses 6,151,000 4,508,000 16,247,000 12,711,000
Loss from operations (6,151,000) (4,508,000) (16,247,000) (12,711,000)
Other income:        
Gain from change in fair value of warrant liability 2,743,000 124,000 1,489,000 3,059,000
Other income, net 10,000 5,000 32,000 5,000
Interest income, net 3,000 5,000 10,000 10,000
Net loss before taxes (3,395,000) (4,374,000) (14,716,000) (9,637,000)
Income tax benefit 0 229,000 0 229,000
Net loss $ (3,395,000) $ (4,145,000) $ (14,716,000) $ (9,408,000)
Net loss per common share - basic and diluted (in dollars per share) $ (0.06) $ (0.09) $ (0.26) $ (0.24)
Weighted average common shares outstanding, basic and diluted (in shares) 61,474,857 45,464,746 56,979,507 39,034,303
Net loss $ (3,395,000) $ (4,145,000) $ (14,716,000) $ (9,408,000)
Other comprehensive income (loss):        
Foreign currency translation 10,000 (3,000) 2,000 (16,000)
Comprehensive loss $ (3,385,000) $ (4,148,000) $ (14,714,000) $ (9,424,000)